Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Nov;1862(11):1300-1309. doi: 10.1016/j.bbalip.2016.09.014. Epub 2016 Sep 23.
Bacterial fatty acid synthesis is essential for many pathogens and different from the mammalian counterpart. These features make bacterial fatty acid synthesis a desirable target for antibiotic discovery. The structural divergence of the conserved enzymes and the presence of different isozymes catalyzing the same reactions in the pathway make bacterial fatty acid synthesis a narrow spectrum target rather than the traditional broad spectrum target. Furthermore, bacterial fatty acid synthesis inhibitors are single-targeting, rather than multi-targeting like traditional monotherapeutic, broad-spectrum antibiotics. The single-targeting nature of bacterial fatty acid synthesis inhibitors makes overcoming fast-developing, target-based resistance a necessary consideration for antibiotic development. Target-based resistance can be overcome through multi-targeting inhibitors, a cocktail of single-targeting inhibitors, or by making the single targeting inhibitor sufficiently high affinity through a pathogen selective approach such that target-based mutants are still susceptible to therapeutic concentrations of drug. Many of the pathogens requiring new antibiotic treatment options encode for essential bacterial fatty acid synthesis enzymes. This review will evaluate the most promising targets in bacterial fatty acid metabolism for antibiotic therapeutics development and review the potential and challenges in advancing each of these targets to the clinic and circumventing target-based resistance. This article is part of a Special Issue entitled: Bacterial Lipids edited by Russell E. Bishop.
细菌脂肪酸合成对于许多病原体至关重要,与哺乳动物的脂肪酸合成不同。这些特征使得细菌脂肪酸合成成为抗生素发现的理想靶点。保守酶的结构差异以及在途径中催化相同反应的不同同工酶的存在,使得细菌脂肪酸合成成为一种窄谱靶点,而不是传统的广谱靶点。此外,细菌脂肪酸合成抑制剂是针对单一靶点的,而不是像传统的单药、广谱抗生素那样针对多个靶点。细菌脂肪酸合成抑制剂的单一靶向性质使得克服快速发展的基于靶点的耐药性成为抗生素开发的必要考虑因素。基于靶点的耐药性可以通过多靶点抑制剂、单一靶点抑制剂的混合物、或者通过使单一靶向抑制剂通过病原体选择性方法具有足够高的亲和力来克服,使得基于靶点的突变体仍然对治疗浓度的药物敏感。许多需要新抗生素治疗选择的病原体编码必需的细菌脂肪酸合成酶。这篇综述将评估细菌脂肪酸代谢中最有前途的抗生素治疗靶点,并回顾将这些靶点推进临床应用和克服基于靶点的耐药性的潜力和挑战。本文是由 Russell E. Bishop 编辑的题为“细菌脂质”的特刊的一部分。